When studying the role of biomarkers in the prognostic value of PTL in 1818 Belgian patients with stage IV CRC, we found that none of the biomarkers (NRAS, KRAS, and BRAF mutational status and MMR) showed a significant interaction with location. This evidence concerns the gene KRAS and colorectal carcinoma.